Therefore, we developed the Ad‐CAIXpromotor‐AIM2 that was an E1B55kD deletion with the E1A gene controlled by CAIXpromotor, armed with the AIM2 gene to enhance the therapeutic efficacy of renal cancer. This evidence concerns the gene AIM2 and renal carcinoma.